Development of Diagnostics and Treatment of Urological Cancers
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Dec 13, 2016
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving the way we diagnose and treat different types of urological cancers, including prostate cancer, kidney cancer, and others. Researchers are using advanced technologies like next-generation sequencing, which helps analyze the genetic information of tumors, to better understand how these cancers behave. The goal is to find out if these new methods can lead to better treatment options and outcomes for patients with urological cancers.
To participate in this trial, you need to be at least 18 years old and have a confirmed diagnosis of a urological cancer from a qualified doctor. It's important that you're able to provide written consent to join the study. If you choose to participate, you will be contributing to important research that could help improve cancer care for others in the future. The trial is currently recruiting participants, and people of all genders are welcome to apply.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient is able to provide written informed consent and is at least 18 years of age
- • 2. The patient must have a verified diagnosis of an urologic cancer by a board-certified clinician
- Exclusion Criteria:
- • 1. The patient is not willing to provide a written informed consent
- • 2. The patient has a severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, Uusimaa, Finland
Patients applied
Trial Officials
Antti S Rannikko, MD, PhD
Principal Investigator
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials